evipedia.ai
← Back

P21 for Health & Longevity

Evidence Review created on 10/04/2026 using AI4L / Opus 5.5

Also known as: P021, P-21, Peptide 021, Peptide 21, PB021, Ac-DGGLAG-NH2

Motivation

P21 (also written P021) is a small, laboratory-made peptide, a chain of four amino acids taken from a natural nerve-growth protein and fitted with a chemical anchor intended to help it pass from the blood into the brain. It is designed to switch on the brain’s own repair signals, encouraging new nerve cells and stronger connections between them, while avoiding the side effects of the full natural protein.

The compound was created in a New York neuroscience laboratory as a possible treatment for Alzheimer’s disease, and its studies in mice and rats have looked at memory, brain aging and Alzheimer-type brain damage. Because it can be administered orally in animal studies and is sold online as a research chemical, it has drawn attention from people seeking to protect memory and thinking as they age.

This review examines what is known about P21’s effects on the aging brain, its potential risks, how it is used outside clinical trials, and how much of the available evidence applies to people.

Benefits - Risks - Protocol - Conclusion

This section lists articles that discuss P21 (P021) in depth: a review by its developers, an independent review, and primary research led outside the developer’s laboratory with the developer as co-author.

Only three items are listed: no content from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) discusses P21, and most other material online consists of vendor pages or repeats the developer’s papers rather than adding independent analysis.

Grokipedia

No Grokipedia article on the P21 (P021) peptide exists. The Grokipedia page titled “p21” covers an unrelated cell-cycle protein (CDKN1A).

Examine

No Examine article on P21 exists. Examine.com does not typically cover investigational research peptides that lack human studies.

ConsumerLab

No ConsumerLab article on P21 exists. ConsumerLab does not typically cover investigational research peptides that are not sold as dietary supplements.

Systematic Reviews

No systematic reviews or meta-analyses for P21 were found on PubMed as of October 2, 2026.

Neither the claimed brain benefits nor the principal risks of P21 are represented by any systematic review or meta-analysis.

Mechanism of Action

P21 is a tetrapeptide (four amino acids) copied from the most active region of CNTF (ciliary neurotrophic factor, a natural nerve-support protein), with an adamantylated glycine (a bulky, fat-soluble chemical cage) added to its end to resist breakdown and cross the blood-brain barrier (the filter that keeps most molecules out of the brain) (Baazaoui & Iqbal, 2017).

  • Primary action: It competitively inhibits LIF (leukemia inhibitory factor, a signal that keeps brain stem cells in an immature state) and raises BDNF (brain-derived neurotrophic factor, the main protein supporting synapse growth and memory) (Kazim & Iqbal, 2016).
  • Downstream effects: BDNF lowers activity of GSK-3β (glycogen synthase kinase-3β, the main enzyme over-phosphorylating tau), reducing tau and amyloid-β (the protein forming Alzheimer plaques) changes, and increases new neurons (neurogenesis) in the dentate gyrus of the hippocampus (the brain’s memory center) (Kazim et al., 2014).
  • Pharmacology: Its half-life (time for levels to halve) in human plasma in a test tube exceeds 3 hours; it survives artificial digestive fluids and reaches the mouse brain within 10 minutes of injection (US patent 9327011). Selectivity beyond LIF and BDNF, distribution outside the brain and human metabolism are unmeasured; as a peptide it is likely cleared by protein-cutting enzymes, not CYP450 (liver drug-metabolizing) enzymes.
  • Competing view: The neurogenesis rationale assumes adult humans form hippocampal neurons, which one group found undetectable (Sorrells et al., 2018) and another, using tightly controlled tissue collection and processing, found abundant (Moreno-Jiménez et al., 2019).

Historical Context & Evolution

CNTF was first studied as a survival factor for nerve cells and was tested in the 1990s as an injected treatment for ALS (amyotrophic lateral sclerosis, a fatal motor-neuron disease). Two large placebo-controlled trials found no slowing of the disease and dose-related appetite loss, weight loss and cough (Miller et al., 1996; ALS CNTF Treatment Study Group, 1996). A modified CNTF was then tested for obesity because of that appetite effect (Ettinger et al., 2003).

To keep CNTF’s nerve-support activity without these effects, Khalid Iqbal and Inge Grundke-Iqbal at the New York State Institute for Basic Research mapped the protein’s active region. This produced Peptide 6, an 11-amino-acid fragment that restored memory in Alzheimer-model mice without changing their plaques or tangles (Blanchard et al., 2010), and the shorter, brain-penetrating P21 (Li et al., 2010).

Between 2010 and 2026 the group published rodent studies in normal aging, Alzheimer, Down syndrome and retinal models, reporting improved memory and less brain pathology. Interest from people pursuing healthy brain aging grew as research-chemical vendors began selling the peptide, although no human study has been published. The first study led outside the developer’s laboratory (Iqbal co-authored), in a genetic epilepsy model, found benefit in cultured cells but limited effects in mice (Mottolese et al., 2024). Current understanding therefore rests almost entirely on one laboratory’s animal work, and replication by independent groups and human trials could still shift it in either direction.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there are no human clinical trials of P21, and every outcome comes from rodent studies.

Medium 🟩 🟩

No benefit reaches Medium: no human trial or human observational study of P21 exists; all evidence is from mice and rats.

Low 🟩

Speculative 🟨

Memory and Learning

Iqbal-group rodent studies report better learning and memory with P21 in normal adult mice, aged rats and Alzheimer-model mice (Li 2010; Bolognin 2014; Kazim 2014). No human data exist; animal evidence only.

Hippocampal Neurogenesis and Synapse Preservation

P21 increased new hippocampal neurons and synaptic proteins in mice and aged rats (Baazaoui 2017; Bolognin 2014). Whether adult humans form such neurons is disputed (Sorrells 2018). Animal evidence only.

Reduced Tau and Amyloid Pathology

P21 lowered abnormal tau and soluble amyloid-β in Alzheimer-model mice, with only a plaque trend when started late (Kazim 2014); early dosing prevented both (Baazaoui 2017). Animal evidence only.

Longer Survival in Alzheimer-Model Mice

Starting P21 at 3 months of age markedly reduced deaths in female Alzheimer-model mice followed for up to 18 months (Baazaoui 2017). No lifespan study in normal animals exists; animal evidence only.

Protection Against Retinal Aging

Chronic P21 reduced macular-degeneration-like damage (photoreceptor loss, pigment-layer atrophy) in aged rats and Alzheimer-model mice (Liu 2019). Single study from the developer’s group; animal evidence only.

Recovery After Brain Injury

Peptide 6, P21’s longer parent peptide, raised new neurons by 80% and improved memory in mice after traumatic brain injury (Chohan 2015). Different compound; no P21 data; animal evidence only.

Early-Life Brain Development ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Prenatal P21 prevented developmental delay in Down syndrome-model mice (Kazim 2017); started after birth, it neither raised BDNF nor fixed brain defects in Cdkl5-deficient mice (Mottolese 2024). For childhood brain disorders, net evidence is inconsistent.

Benefit-Modifying Factors

  • Genetic polymorphisms: The BDNF Val66Met variant (a common change that lowers activity-driven BDNF release) impairs hippocampal memory (Egan et al., 2003); because P21 acts through BDNF, carriers might respond differently. APOE4 (a variant of a fat-transport gene; the main genetic Alzheimer risk) is unstudied.
  • Baseline biomarkers: No biomarker predicts response. In animals, effects were clearest where baseline function was impaired (aged or disease-model animals), although normal adult mice also improved (Li et al., 2010).
  • Sex differences: The Alzheimer-model studies used female mice only (Kazim et al., 2014), so effects in males of those models are largely unknown.
  • Pre-existing conditions: Response varied by disease model: strong in Alzheimer and Down syndrome models, limited in CDKL5 deficiency (Mottolese et al., 2024). Effects in people with established dementia are unknown.
  • Age: Rats aged 22–24 months still responded (Bolognin et al., 2014), but the developer’s group argues that starting before major brain loss works best (Baazaoui & Iqbal, 2018).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human has received P21 in a published trial, so no human adverse-event data exist from any research group.

Medium 🟥 🟥

No risk reaches Medium: the only human adverse-event data come from trials of the parent protein CNTF, which are indirect evidence.

Low 🟥

Appetite Loss and Weight Loss ⚠️ Conflicted

Injected CNTF, P21’s parent protein, caused dose-related appetite loss and weight loss in placebo-controlled trials by Miller and Ettinger (Miller 1996; Ettinger 2003). This is indirect, parent-compound evidence. The developer’s review reports none in rodents given P21 (Kazim & Iqbal 2016). Net, the appetite effect is unconfirmed for P21.

Magnitude: Recombinant variant CNTF changed body weight by −4.1 kg at 1.0 µg/kg/day versus +0.1 kg with placebo over 12 weeks (within-group means, not compared between groups; the study reported only a significant dose-trend test, a check of whether weight loss grew with dose); adverse events occurred in 78–93% of treated patients versus 75% with placebo (Ettinger et al., 2003).

Speculative 🟨

Contaminated or Mislabeled Product

P21 is sold by unregulated research-chemical vendors, so content, sterility and endotoxin (fever-causing bacterial toxin) are unverified. Semaglutide from illegal online sellers had low purity and endotoxin in every vial (Ashraf 2024). Indirect evidence only.

Growth Signaling and Tumor Promotion

P21 raises BDNF, whose receptor TrkB drives growth of several cancers (Malekan 2023). The developer’s review reports no CNTF- or BDNF-type adverse effects in rodents (Kazim & Iqbal 2016); basis is mechanistic only.

Impaired Embryo Implantation

P21 inhibits LIF signaling, and female mice lacking LIF cannot implant embryos (Stewart 1992). No P21 fertility or pregnancy study exists; basis is mechanistic only.

Immune Reaction to the Peptide

Peptide drugs can trigger antibodies. Aged rats given oral P21 showed no detectable immune reaction (Khatoon 2015). Human antibody responses after injection or nasal use are untested; basis is animal data only.

Headache, Nasal Irritation and Mood Changes

A community protocol guide lists nasal irritation (intranasal use), mild headache, fatigue, vivid dreams and mood fluctuations as user-reported effects (Peptide Initiative). No controlled study has assessed them; basis is anecdotal reports only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been studied with P21. Inherited cancer-predisposition variants (for example BRCA1 or BRCA2, genes that repair DNA damage) could matter given the theoretical growth-signal risk.
  • Baseline biomarkers: Low baseline body weight leaves less reserve if CNTF-like appetite loss occurs; abnormal baseline liver or kidney tests make new problems harder to attribute.
  • Sex differences: Women able to become pregnant carry the theoretical LIF-related implantation risk. Most Alzheimer-model safety data come from female mice (Kazim et al., 2014).
  • Pre-existing conditions: Active or past cancer (theoretical growth-signal risk), allergic or autoimmune disease (immune reactions), and nasal disease (intranasal route) may raise risk.
  • Age: Older adults have higher background cancer rates and less reserve against weight loss; aged rats given P21 showed no detectable immune reaction (Khatoon et al., 2015).

Key Interactions & Contraindications

No human interaction or pharmacokinetic study of P21 exists, so every interaction below is inferred from mechanism.

  • Pan-Trk cancer drugs, which block all Trk growth receptors (larotrectinib, entrectinib): Avoid (theoretical). P21 raises BDNF signaling through TrkB, which these drugs block (Malekan et al., 2023); consequence could be reduced anticancer effect. P21 is typically stopped during such treatment.
  • GSK-3 inhibitors (lithium carbonate): Caution (theoretical). Additive GSK-3β inhibition with unknown consequences for mood and cell growth. Lithium levels and mood are monitored if combined.
  • Antidepressants that raise BDNF (sertraline, escitalopram): Monitor (theoretical). Additive BDNF stimulation could shift mood or sleep. P21 is usually started only once the antidepressant dose is stable.
  • Fertility medications (clomiphene citrate, letrozole, follitropin alfa): Avoid (theoretical). LIF inhibition could reduce embryo implantation (Stewart et al., 1992). P21 is stopped before any conception attempt.
  • Over-the-counter nasal decongestants (oxymetazoline, phenylephrine sprays): Caution (theoretical). Vessel narrowing may reduce intranasal P21 absorption, giving lower, unpredictable doses. Use is separated by several hours.
  • TrkB-activating supplements (7,8-dihydroxyflavone): Caution (theoretical). Additive TrkB stimulation compounds the theoretical growth-signal risk. Combining is avoided.
  • Lithium orotate supplements: Caution (theoretical). Additive GSK-3β inhibition, as with prescription lithium, could shift mood or cell growth. Combining is avoided, or mood is monitored.
  • Other nootropic (memory-enhancing) peptides (Semax, Cerebrolysin, Dihexa): Caution (theoretical). Additive neurotrophic signaling with untested combined safety, and each adds contamination risk. One compound at a time is the usual approach.
  • Aerobic exercise: No harm expected; potentially additive (theoretical). Running raises hippocampal neurogenesis in mice (van Praag et al., 1999); no mitigation is needed.

Populations who should avoid P21:

  • Women who are pregnant, breastfeeding or trying to conceive
  • People with active cancer or receiving cancer treatment
  • Children and adolescents
  • People with a history of allergic reaction to peptide products
  • People who are underweight or have an eating disorder

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Verified sourcing: Only batches with an independent certificate showing identity and purity by HPLC (high-performance liquid chromatography) and mass spectrometry, plus endotoxin testing, are used; this mitigates contaminated or mislabeled product (Ashraf et al., 2024).
  • Low starting dose: Use starts at 100–250 µg daily for 2 weeks before any increase, to limit unknown dose-related adverse events and immune reactions.
  • Single-compound use: Other peptides or nootropics are not stacked for at least the first cycle, preventing additive growth-signal effects and making any adverse event attributable.
  • Weight tracking: Weekly weighing, with use stopped if unintended weight loss exceeds 5% of starting weight, mitigates CNTF-class appetite loss.
  • Pregnancy exclusion: A pregnancy test before starting and reliable contraception during use and for 2 weeks after prevent the theoretical implantation risk.
  • Cancer screening first: Age-appropriate cancer screening is completed before starting, and use is avoided with active cancer, mitigating the theoretical tumor-promotion risk.
  • Sterile handling: Injection uses bacteriostatic water, single-use needles and alcohol swabs; reconstituted vials are refrigerated and discarded after 28 days, preventing injection-site infection.
  • Stop on reaction: Use stops at rash, swelling, fever or breathing difficulty, with prompt medical assessment, mitigating immune reactions.

Therapeutic Protocol

Timing, cycling and titration steps below reflect common practice; doses are cited to their sources.

  • Animal research regimen: Mice received 60 nmol P21 per gram of diet, about 2.7 g of diet daily, for up to 12 months (US patent 9327011). No human-equivalent dose has been validated.
  • Community intranasal regimen: 500–1000 µg once daily for 8–12 weeks, as listed by Michael Carroll of the Peptide Initiative (Peptide Initiative).
  • Community subcutaneous regimen: An 8-week protocol at 375 µg/day, as listed by the vendor-affiliated Biomogging guide (Biomogging).
  • Alternative approach: The conventional drug-development path keeps P21 in preclinical testing until formal human trials (Lozupone et al., 2023); community self-experimentation proceeds without them. Both rest on the same rodent evidence.
  • Origin of the approach: Khalid Iqbal’s laboratory developed P21; its use outside research was popularized by online peptide vendors and nootropic communities rather than by a named clinician.
  • Route: Oral use worked in rodents (Bolognin et al., 2014), but human oral bioavailability is unknown; community users mostly choose intranasal or subcutaneous injection.
  • Time of day: No data exist; morning dosing is common practice.
  • Half-life: Over 3 hours in human plasma in a test tube (US patent 9327011); human half-life after dosing is unmeasured.
  • Single or split dose: Community protocols use one daily dose; no data compare split dosing.
  • Genetic polymorphisms: No variant (BDNF Val66Met, APOE4) is known to change the dose; none has been tested.
  • Sex differences: No sex-specific dosing exists; Alzheimer-model efficacy data come from female mice only.
  • Age: Aged rats responded to standard rodent dosing (Bolognin et al., 2014); older adults typically start at the low end.
  • Baseline biomarkers: No biomarker guides dose; low body weight favors the lowest dose.
  • Pre-existing conditions: Cancer history, pregnancy plans or nasal disease change whether and how the peptide is used.

Discontinuation & Cycling

  • Duration: Community use is short-term, in 8–12-week cycles (Peptide Initiative); rodent studies ran continuously for up to 18 months (Baazaoui & Iqbal, 2017).
  • Withdrawal effects: None have been reported in animals, and no human data exist.
  • Tapering: Not needed by any known mechanism; stopping abruptly is common practice.
  • Cycling: Breaks of at least 4 weeks between cycles are common practice to limit cumulative exposure, not to preserve efficacy; no tolerance has been shown.

Sourcing and Quality

  • Source: No pharmaceutical-grade (made under good manufacturing practice) product is commercially available; all supply comes from research-chemical vendors labeling it not for human use.
  • Purity and testing: Useful markers are batch-specific certificates showing identity by mass spectrometry, purity by HPLC and a low endotoxin result, ideally from an independent laboratory; three semaglutide vials from illegal online pharmacies, labeled 99% pure, measured 7.7–14.37% (Ashraf et al., 2024).
  • Formulation: It is sold as freeze-dried powder for injection or as nasal spray; the developer’s studies used oral feed with peptide purified to over 96% (US patent 9327011).
  • Brands: No vendor or compounding pharmacy offers independently verified P21 products, and no product is sold by its developer, Phanes Biotech.

Practical Considerations

  • Time to effect: Rodent studies measured effects after 30 days of the parent Peptide 6 (Chohan et al., 2015) and after 6–12 months of P21 (Kazim et al., 2014); human onset is unknown.
  • Common pitfalls: Confusing P21 the peptide with p21 the cell-cycle protein, or with Peptide 6; buying untested products; stacking several peptides; and expecting immediate effects.
  • Regulatory status: P21 remains a preclinical compound (Lozupone et al., 2023), covered by a US patent assigned to the Research Foundation for Mental Hygiene (US patent 9327011) and developed by Phanes Biotech (Phanes Biotech).
  • Access: Pharmaceutical-grade product is unavailable; access is limited to research-chemical vendors of unverified quality.

Interaction with Foundational Habits

  • Sleep: No direct interaction is known. Indirectly, poor sleep suppresses the same hippocampal plasticity P21 targets, so sleep loss may blunt any benefit; community reports of vivid dreams are anecdotal. Morning dosing is common practice.
  • Nutrition: No direct interaction is known. Rodents took P21 mixed in food and it resists stomach and intestinal fluids (US patent 9327011). Weight and appetite tracking matters given the parent protein’s appetite effect.
  • Exercise: Potentially potentiating. Aerobic exercise enlarged the hippocampus by 2% in older adults alongside higher serum BDNF (Erickson et al., 2011), the same pathway P21 targets; no combined study exists.
  • Stress management: Indirect. Chronic stress hormones lower BDNF and hippocampal neurogenesis, opposing P21’s intended effect; stress reduction may support response. No P21-specific data exist.

Monitoring Protocol & Defining Success

Before starting, baseline testing records body weight, a liver and kidney panel, a blood count and, for women able to conceive, a pregnancy test; an optional serum BDNF and plasma p-tau217 (a blood form of tau linked to Alzheimer pathology) give a personal reference point, and a validated cognitive test (for example the Montreal Cognitive Assessment or a computerized battery) documents starting performance.

Ongoing monitoring follows this cadence: weight weekly; repeat blood tests at 4 weeks, at the end of each 8–12-week cycle, then every 6 months while use continues; cognitive testing at the end of each cycle. Success means stable safety tests plus an improvement over the person’s own baseline on the same cognitive test; no target result has been validated for P21.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7–55 U/L (standard reference range) Safety check: a rise stops use ALT (alanine aminotransferase, a liver enzyme); fasting not required; pair with AST; ranges vary by laboratory
AST 8–48 U/L (standard reference range) Safety check: a rise stops use AST (aspartate aminotransferase, a liver and muscle enzyme); intense exercise within 48 hours can raise it
Creatinine 0.59–1.35 mg/dL (standard reference range) Safety check: a rise stops use Kidney filtration marker; lower range applies to women; pair with eGFR (estimated glomerular filtration rate)
White blood cell count 3.4–9.6 × 10⁹/L (standard reference range) Safety check: a rise with fever stops use Part of the CBC (complete blood count); may flag infection from contaminated injections
Serum hCG Negative, below 5 IU/L (standard reference range) Safety check: a positive result stops use hCG (human chorionic gonadotropin, the pregnancy hormone); for women able to conceive, before starting
Serum BDNF No established target; track change from own baseline Expected to change: P21 raises BDNF in animals Serum level reflects platelet stores and may not mirror brain levels; draw at the same time of day
Plasma p-tau217 No established target; track change from own baseline Expected to change: P21 lowered tau in animals Fasting not required; most informative when baseline is elevated; assay results differ between laboratories

Qualitative markers tracked alongside the tests:

  • Memory for names, appointments and new information
  • Word-finding and mental clarity
  • Sleep quality and dream changes
  • Mood stability
  • Appetite and unintended weight change
  • Nasal irritation or injection-site reactions
  • Headaches

Emerging Research

  • First human trials: No P21 trial is registered on ClinicalTrials.gov (searched October 2026; no NCT ID, the registry’s trial number, exists). Phanes Biotech, co-founded by Iqbal, is developing it (Phanes Biotech). A clean safety trial would allow risks to be graded on human data; toxicity would strengthen the risk case.
  • Brain imaging in mice: Falangola et al., 2026 found diffusion MRI (a scan of water movement in brain tissue) changes suggesting better white-matter integrity in Alzheimer-model mice given P21 from 2.5 to 8 months of age. A correction notice amending page 9 was published in 2026. Such scans could serve as human trial markers.
  • Replication outside the developer’s laboratory: Mottolese et al., 2024, led in Bologna but co-authored by Iqbal with a Phanes Biotech affiliation, found limited benefit in live mice; fully independent studies could either confirm or weaken the case.
  • Human neurogenesis debate: Whether adult humans form hippocampal neurons (Sorrells et al., 2018 versus Moreno-Jiménez et al., 2019) determines how plausible P21’s central rationale is in people.
  • Parent-protein precedent: A Cochrane review of CNTF in ALS found no survival benefit (relative risk, the death rate with CNTF divided by that with placebo, 1.07; 95% CI, the range likely to hold the true value, 0.81–1.41) and more adverse events at high doses (Bongioanni et al., 2004); rodent promise may not translate.

Conclusion

P21 is a small laboratory-made peptide derived from a natural nerve-growth protein and designed to strengthen the brain’s own repair signals. For health-focused adults interested in protecting memory and brain function with age, it offers an appealing biological idea backed by a substantial body of animal work.

In mice and rats, the reported benefits include better memory, more new brain cells, less Alzheimer-type protein build-up, longer survival in an Alzheimer model and healthier retinas. None of this has been tested in people, so every benefit remains speculative, and one animal study led by another laboratory, with the developer as co-author, found weaker effects than the developer’s studies.

The risks are equally uncertain. The parent protein caused appetite and weight loss in human trials, products sold online may be impure or contaminated, and the peptide’s growth-promoting and fertility-related actions raise theoretical concerns about tumor growth and early pregnancy. Long-term safety in people is unknown.

The quality of the evidence is limited. Nearly all studies come from a single laboratory whose lead scientist is a named inventor on patents covering the compound and co-founded the company developing it, a financial interest that bears on how the findings are read. No human data exist, the few studies led by outside laboratories still include the developer as co-author and give mixed results, and no pharmaceutical-grade product is available. For now, P21 is an experimental compound whose promise and hazards both rest on animal studies and theory rather than on any experience in people.

Top - Benefits - Risks - Protocol